CORMEDIX INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
CORMEDIX INC. (CRMD) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $0.00.
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $0.00.
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$805.00, a 135.25% decline year-over-year.
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $2.28K.
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$2.00K, a 171.23% decline from fiscal 2023.
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $2.81K.
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$8.68K.
- CORMEDIX INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2021 was -$12.92K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | ||||||
| 2025-09-30 | $1.33K 10-Q · filed 2025-11-12 | ||||||
| 2025-06-30 | $1.00K 10-Q · filed 2026-08-13 | $1.06K 10-Q · filed 2025-08-07 | |||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $229.00 10-Q · filed 2025-05-06 | |||||
| 2024-12-31 | -$2.00K 10-K · filed 2026-03-05 | -$1.71K 10-K · filed 2025-03-25 | |||||
| 2024-09-30 | -$478.00 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | -$893.00 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | -$805.00 10-Q · filed 2025-05-06 | ||||||
| 2023-12-31 | $2.81K 10-K · filed 2025-03-25 | ||||||
| 2023-09-30 | $385.00 10-Q · filed 2024-10-30 | ||||||
| 2023-06-30 | $2.53K 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | $2.28K 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | -$8.68K 10-K · filed 2024-03-12 | ||||||
| 2022-09-30 | -$24.46K 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | -$13.55K 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | -$3.18K 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | -$12.92K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |